A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients
A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of sunitinib combined with docetaxel versus docetaxel, administered as first-line treatment, in patients with unresectable locally recurrent or metastatic breast cancer.
Inclusion Criteria:
Exclusion Criteria:
Berkely, California 94704, United States
Burnos Aires, C1426ANZ, Argentina
Bogota, Cundinamarca, Colombia
Kuzmolovo, Vsevolozhsk District, Leningradskaya Oblast' 188663, Russia